Childhood-Onset Takayasu Arteritis: Clinical Features of Disease and Relapse Risk Factors
<b>Background:</b> Takayasu’s arteritis (TA) is a systemic vasculitis that primarily affects the aorta and major arteries. Despite aggressive treatment with glucocorticoids (GCs) and non-biological disease-modifying antirheumatic drugs (nbDMARDs), about 30% of patients experience resista...
Saved in:
| Main Authors: | Vera Podzolkova, Galina Lyskina, Olga Shpitonkova, Angelina Polyanskaya, Svetlana Chebysheva, Marina Shakhnazarova, Jinbo Zhao, Aleksandr Suvorov, Vera Khudoroshkova, Natalia Geppe |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/12/1/70 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tocilizumab in Extracranial Giant-Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
by: Carmen Lasa-Teja, et al.
Published: (2025-01-01) -
Difficulties in the Diagnosis and Management of Patients with Takayasu’s Arteritis: A Description of a 5-Year Clinical Follow-Up
by: A. V. Petrov, et al.
Published: (2023-10-01) -
Anesthetic Management of Parturients with Takayasu’s Arteritis: A Series of Three Cases
by: Nilesh M. Solanki, et al.
Published: (2025-01-01) -
INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01) -
The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01)